Product nameHuman MMP13 Matched Antibody Pair Kit
See all MMP13 kits
Assay typeELISA set
Range31.2 pg/ml - 2000 pg/ml
Species reactivityReacts with: Human
Matched Antibody Pair Kits include a capture and a biotinylated detector antibody pair, along with a calibrated protein standard, suitable for sandwich ELISA. The Matched Antibody Pair Kit can be used to quantify native and recombinant human MMP13.
Matched antibody pair kits and reagents deliver consistent, specific, and sensitive results.
- Batch-to-batch consistency: only recombinant monoclonal antibodies are used in our matched antibody pairs.
- Specificity: antibody pairs are screened in plasma and serum to ensure specificity in complex samples.
- Sensitivity: benchmarked against commercially available antibody pairs to ensure equivalent or superior performance compared with the competition.
Additional buffers and plates are required for the assay. An accessory pack can be purchased which includes buffer reagents required to perform 10 x 96-well plate sandwich ELISAs (ab210905).
For additional information on the performance of the antibody pair used in this kit, please see our equivalent SimpleStep ELISA® (ab221839) which uses the same antibody pair.
To receive an electronic copy of the Certificate of Analysis, please send an email with "CoA for matched antibody pair kit" in the subject line and the desired product number and lot number in the body of the email.
Tested applicationsSuitable for: ELISAmore details
Storage instructionsStore at -20°C. Please refer to protocols.
Components 10 x 96 tests 2 x 96 tests Human MMP13 Capture Antibody 1 x 100µg 1 x 20µg Human MMP13 Detector Antibody 1 x 25µg 1 x 5µg Human MMP13 Lyophilized Protein 1 vial 1 vial
FunctionDegrades collagen type I. Does not act on gelatin or casein. Could have a role in tumoral process.
Tissue specificitySeems to be specific to breast carcinomas.
Involvement in diseaseDefects in MMP13 are the cause of spondyloepimetaphyseal dysplasia Missouri type (SEMD-MO) [MIM:602111]. A bone disease characterized by moderate to severe metaphyseal changes, mild epiphyseal involvement, rhizomelic shortening of the lower limbs with bowing of the femora and/or tibiae, coxa vara, genu varum and pear-shaped vertebrae in childhood. Epimetaphyseal changes improve with age.
Defects in MMP13 are the cause of metaphyseal anadysplasia type 1 (MANDP1) [MIM:602111]. Metaphyseal anadysplasia consists of an abnormal bone development characterized by severe skeletal changes that, in contrast with the progressive course of most other skeletal dysplasias, resolve spontaneously with age. Clinical characteristics are evident from the first months of life and include slight shortness of stature and a mild varus deformity of the legs. Patients attain a normal stature in adolescence and show improvement or complete resolution of varus deformity of the legs and rhizomelic micromelia.
Sequence similaritiesBelongs to the peptidase M10A family.
Contains 4 hemopexin-like domains.
DomainThe conserved cysteine present in the cysteine-switch motif binds the catalytic zinc ion, thus inhibiting the enzyme. The dissociation of the cysteine from the zinc ion upon the activation-peptide release activates the enzyme.
Cellular localizationSecreted > extracellular space > extracellular matrix.
- Information by UniProt
- CLG 3
- Collagenase 3
Our Abpromise guarantee covers the use of ab222258 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|ELISA||Use at an assay dependent concentration.|
ab222258 has not yet been referenced specifically in any publications.